Cantor Fitzgerald Starts Nuvation Bio Inc (NUVB) at Overweight

Cantor Fitzgerald analyst Li Watsek initiates coverage on Nuvation Bio Inc (NYSE: NUVB) with a Overweight rating.

The analyst comments "We initiate coverage of Nuvation Bio (NUVB) at Overweight. Nuvation is a low-risk, high-reward commercial-stage oncology story built on two best-in-class targeted therapies. We believe the Street materially undervalues the size of both markets, driven in part by multi-year treatment duration. Ibtrozi (taletrectinib), a next-generation ROS1 inhibitor launched in 2025, provides the valuation floor. We believe growing 1L use in ROS1+ NSCLC (non-small cell lung cancer) and a multi-year duration of therapy should drive U.S. peak sales of $965M (Cantor est.), which alone is sufficient to support upside to the current ~$2.6B market cap. Safusidenib, a differentiated IDH1 inhibitor in pivotal Phase 3 development for IDH1-mutant glioma, is the mispriced prize: a best-in-class profile, de-risked by Servier's approved Voranigo/INDIGO precedent, with ~$1.9B in peak sales potential (Cantor est.) across the broadest development program in the class. The combination of a growing commercial floor and blockbuster pipeline optionality makes NUVB a compelling, mispriced risk/reward name, in our view. We believe there's also substantial strategic interest for a commercial-targeted oncology company like Nuvation (e.g., acquisitions of Turning Point, Mirati, Day One, Chimerix). Our DCF derives a 12-month equity value of $12/share, implying 73% upside."

For an analyst ratings summary and ratings history on Nuvation Bio Inc click here. For more ratings news on Nuvation Bio Inc click here.

Shares of Nuvation Bio Inc closed at $6.83 yesterday.

You May Also Be Interested In

• BofA maintains underperform ratings on six BDC stocks
• BIGG Digital Assets to rename as Surge Digital, consolidate shares
• CoVolt Power files for proposed IPO